Prosecution Insights
Last updated: November 04, 2026
Application No. 18/455,407

TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION

Non-Final OA §112
Filed
Aug 24, 2023
Priority
Feb 12, 2020 — provisional 62/975,265 +3 more
Examiner
DICKINSON, PAUL W
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alzeca Biosciences LLC
OA Round
2 (Non-Final)
63%
Grant Probability
Moderate
2-3
OA Rounds
1m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
665 granted / 1052 resolved
+3.2% vs TC avg
Moderate +10% lift
Without
With
+9.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
48 currently pending
Career history
1099
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1052 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant’s arguments, filed 8/13/2026 have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objects are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: The closest prior art to claims is Inayama (Journal of Medicinal Chemistry, 1976; document already in record). Although Inayama teaches a liposomal composition comprising the compound PNG media_image1.png 256 366 media_image1.png Greyscale (abstract; experimental section; Table 2, Compound 23), it fails to teach or fairly suggest a liposomal composition comprising the presently claimed compounds. Claims 21-25, 39 and 47-49 are allowable. Claims 26-29, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions I-II as set forth in the Office action mailed on 8/13/2026, is hereby withdrawn and claims 26-29 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 26-29 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 26, there is no description of “detectable quantity.” There is no art-defined definition of “detectable quantity” in the prior art, nor is there is description in the present application as to what parameters under what conditions are considered a “detectable quantity” and what parameters under what conditions are not considered a ”detectable quantity.” Further, there is insufficient written description for “allowing sufficient time for the liposomal composition to be associated with one or more alpha-synuclein deposits. There is no art-defined definition of what criteria need to take place in order for a liposomal composition to be considered “associated” with on more alpha-synuclein deposits, nor has the application described what criteria need to take place in order for a liposomal composition to be considered “associated” with on more alpha-synuclein deposits. Further regarding claim 27, there is no art-defined standard of what constitutes “a healthy subject,” nor has the application described what qualities or traits a person needs to have in order to be considered a “healthy subject” within the meaning of the invention. Further regarding claim 28, the term” a statistically significant difference in signal intensity” is not described in the application, nor is there description of what differences in signal intensity are and are not considered significant within the meaning of the invention. Further regarding claim 28, there is no description in the application of “baseline sample,” and what qualities a sample needs to have in order to be considered a baseline sample. Conclusion APPLICANTS AMENDMENT NECESSITATED THE NEW GROUNDS OF REJECTION. THIS ACTION IS THEREFORE MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL W DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on M-F 9 AM to 7:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL W DICKINSON/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Aug 24, 2023
Application Filed
Feb 06, 2024
Response after Non-Final Action
May 12, 2026
Non-Final Rejection mailed — §112
Aug 13, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §112
Oct 21, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779046
HETEROBIFUNCTIONAL MONODISPERSED POLYETHYLENE GLYCOL HAVING PEPTIDE LINKER
4y 7m to grant Granted Nov 03, 2026
Patent 12778948
DISCRETE PEG CONSTRUCTS
2y 10m to grant Granted Nov 03, 2026
Patent 12734255
RADIOPAQUE POLYMERS WITH ENHANCED RADIOPACITY
7y 4m to grant Granted Sep 15, 2026
Patent 12734257
TERAGNOSTIC METHOD FOR CANCER PATIENTS
2y 0m to grant Granted Sep 15, 2026
Patent 12708606
LITHIUM FLUORIDE NANOPARTICLES FOR THE PROTECTION OF CHONDROCYTES IN OSTEOARTHRITIS
3y 4m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
63%
Grant Probability
73%
With Interview (+9.5%)
3y 3m (~1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1052 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month